Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1985 1
1986 2
1987 1
1988 8
1989 7
1990 6
1991 2
1992 1
1993 5
1994 2
1995 5
1996 5
1997 6
1998 3
1999 6
2000 3
2001 3
2005 1
2006 3
2007 4
2008 1
2009 1
2010 4
2011 3
2012 1
2013 3
2014 1
2015 5
2016 12
2017 16
2018 7
2019 16
2020 11
2021 26
2022 14
2023 7

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, Toki T, Yamaguchi J, Kitamura M, Kamei R, Fujitani T, Honda T, Shibutani T, Muramatsu S, Nakada T, Goto R, Takahashi S, Yamaguchi M, Hamada H, Noguchi Y, Murakami M, Abe Y, Agatsuma T. Okajima D, et al. Among authors: shibutani t. Mol Cancer Ther. 2021 Dec;20(12):2329-2340. doi: 10.1158/1535-7163.MCT-21-0206. Epub 2021 Aug 19. Mol Cancer Ther. 2021. PMID: 34413126 Free PMC article.
DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.
Yamato M, Hasegawa J, Maejima T, Hattori C, Kumagai K, Watanabe A, Nishiya Y, Shibutani T, Aida T, Hayakawa I, Nakada T, Abe Y, Agatsuma T. Yamato M, et al. Among authors: shibutani t. Mol Cancer Ther. 2022 Apr 1;21(4):635-646. doi: 10.1158/1535-7163.MCT-21-0554. Mol Cancer Ther. 2022. PMID: 35149548 Free PMC article.
Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate.
Iida K, Abdelhamid Ahmed AH, Nagatsuma AK, Shibutani T, Yasuda S, Kitamura M, Hattori C, Abe M, Hasegawa J, Iguchi T, Karibe T, Nakada T, Inaki K, Kamei R, Abe Y, Nomura T, Andersen JL, Santagata S, Hemming ML, George S, Doi T, Ochiai A, Demetri GD, Agatsuma T. Iida K, et al. Among authors: shibutani t. Cancer Discov. 2021 Jun;11(6):1508-1523. doi: 10.1158/2159-8290.CD-20-1434. Epub 2021 Feb 12. Cancer Discov. 2021. PMID: 33579785 Clinical Trial.
[[Nuclear Medicine] 3. Cardiac Phantom].
Shibutani T. Shibutani T. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2022;78(5):513-519. doi: 10.6009/jjrt.2022-2019. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2022. PMID: 35598960 Free article. Japanese. No abstract available.
Group C. Consensus paper. Periodontal regeneration--fact or fiction?
Murakami S, Bartold M, Meyle J, Agarwal R, Anagnostou F, Bakalyan V, Bunyaratavej P, Chitguppi R, Darby I, Gamal A, Jacob S, Jin Y, John J, Kale R, Liechter J, Minh NT, Nagata T, Nazreth B, Nishida M, Pack A, Patnaik S, Shibutani T, Singh P, Soeroso Y, Spahr A, Yang YC, Yeung S. Murakami S, et al. Among authors: shibutani t. J Int Acad Periodontol. 2015 Jan;17(1 Suppl):54-6. J Int Acad Periodontol. 2015. PMID: 25764592 No abstract available.
Novel anti-EPHA2 antibody, DS-8895a for cancer treatment.
Hasegawa J, Sue M, Yamato M, Ichikawa J, Ishida S, Shibutani T, Kitamura M, Wada T, Agatsuma T. Hasegawa J, et al. Among authors: shibutani t. Cancer Biol Ther. 2016 Nov;17(11):1158-1167. doi: 10.1080/15384047.2016.1235663. Epub 2016 Sep 21. Cancer Biol Ther. 2016. PMID: 27653549 Free PMC article.
190 results